UK Health Security Agency

All influenza vaccines marketed in the UK for the 2025 to 2026 season

Supplier	Product	Vaccine type	Age indications	Ovalbumin content micrograms/dose	Contact details
AstraZeneca UK Ltd	Fluenz®	Trivalent LAIV (live attenuated influenza vaccine) supplied as nasal spray suspension	From 24 months to less than 18 years of age	Less than 0.024 micrograms per 0.2 ml dose	0845 139 0000
Sanofi	Vaxigrip[1]	TIVe (standard egg-grown trivalent influenza vaccine), split virion, inactivated	From 6 months	Equal to or less than 0.05 micrograms per 0.5 ml dose	0800 854 430
Viatris	Influvac® sub-unit TIV▼	TIVe (standard egg-grown trivalent influenza vaccine) surface antigen, inactivated	From 6 months	Equal to or less than 0.1 micrograms per 0.5 ml dose	0800 358 7468
CSL Seqirus UK	Cell-based Trivalent Influenza Vaccine Seqirus▼	TIVc (cell-based Trivalent influenza vaccine) surface antigen, inactivated	From 6 months	Egg-free	0345 0093 804
Sanofi	Supemtek TIVr▼[1]	Supemtek TIV (trivalent influenza vaccine (recombinant, prepared in cell culture))	From 18 years	None	0800 854 430
Sanofi	Efluelda TIV-HD▼[1]	TIV-HD (High-dose egg-grown trivalent influenza vaccine), split virion, inactivated 60 micrograms HA/strain	From 60 years	Equal to or less than 1 microgram per 0.5ml dose	0800 854 430
CSL Seqirus UK	Adjuvanted Trivalent Influenza Vaccine Seqirus ▼	aTIV (adjuvanted egg-grown Trivalent influenza vaccine) surface antigen, inactivated, adjuvanted with MF59C.1	From 50 years	Equal to or less than 1 microgram per 0.5ml dose	0345 0093 804

[1] Sanofi intends to supply trivalent formulations for the 2025 to 2026 season. Relevant license applications are under assessment and Medicines and Healthcare products Regulatory Agency (MHRA) approval is pending. Other potential formulations (quadrivalent) would have the same antigen content per strain, and ovalbumin content threshold (where relevant) as presented in the table.

UK Health Security Agency gateway number 2024-1002, February 2025.